Novavax Shares Skyrocket Following $1.2 Billion Sanofi Licensing Deal

Novavax Inc. experienced a dramatic surge in its stock price on Friday, following a significant licensing agreement with French pharmaceutical giant Sanofi. The deal, valued at up to $1.2 billion, includes a combination of upfront cash, milestone payments, and royalties, centered around Novavax's COVID-19 vaccine.

Under the terms of the agreement, Sanofi will invest $70 million for a 4.9% stake in Novavax, placing the biotech firm's valuation at approximately $1.4 billion. This valuation is nearly double its market capitalization of about $628 million as of Thursday's close, a stark contrast to its peak value of $20 billion in 2021.

Novavax's shares surged to $10.11 in pre-market trading, a significant recovery for the company, which had previously issued a going concern notice in February of the previous year. This notice had cast doubt on its ability to continue as a going concern due to financial strains and delays in getting its COVID-19 vaccine to market.

The strategic partnership will allow Sanofi to co-market Novavax's vaccine and potentially integrate it with its flu vaccines into a combination shot. This move could fortify Sanofi's vaccine portfolio as it faces increasing competition from rivals like Pfizer and Moderna, who are also developing combination vaccines.

Analysts from Barclays highlighted the strategic importance of the deal for Sanofi, noting the potential to strengthen its position in the flu vaccine market with the addition of a COVID-19 combination vaccine.

Despite the positive news from the deal, Novavax has revised its 2024 revenue projections downward, from the previously expected range of $800 million to $1 billion, to a new range of $400 million to $600 million, excluding potential revenues from the Sanofi agreement.

Furthermore, Novavax reported a first-quarter net loss of $148 million, an improvement from a loss of $294 million in the same quarter last year, reflecting some stabilization in its financial performance.

The deal represents a significant turnaround for Novavax, providing it with a much-needed financial boost and strategic partnership to navigate the competitive vaccine market.